BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Cellceutix 

100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


SEARCH JOBS










 Company News
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014 11:31:24 AM
Cellceutix (CTIX) Anti-Psoriasis Drug Prurisol Meets Primary Endpoint Of Clinical Trial 8/7/2014 10:16:59 AM
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014 11:31:29 AM
Cellceutix (CTIX) Announces Breakthrough In The Formulation Of Its Novel Antibiotic Brilacidin™, Plans Studies To Treat Diabetic Foot Ulcers 7/15/2014 11:29:41 AM
Cellceutix (CTIX) Brilacidin ABSSSI Trial Gets Positive Review By Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 7/7/2014 12:31:02 PM
Cellceutix (CTIX) Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 6/23/2014 8:51:11 AM
Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6/16/2014 11:19:51 AM
Cellceutix (CTIX) Completes Patient Enrollment In Clinical Trial Of Prurisol 6/2/2014 10:52:08 AM
Cellceutix (CTIX) Signs Material Transfer Agreements For Defensin Mimetic Compounds With Leading Universities 5/27/2014 9:06:04 AM
Cellceutix (CTIX) Plans For Entry In Diabetic Foot Wound And Ulcer Market 5/20/2014 9:53:10 AM
12345678910...